Lupin gets ANDA approval for Suprax Cefixime

New Delhi, Apr 12: Pharma major Lupin Ltd today said the US Food and Drug Administration (USFDA) has approved the company's application for Suprax Cefixime following which commercial shipments of the product have commenced.

''The incidence of respiratory infections is high in children and physicians need products that offer greater patient convenience and compliance,'' Lupin Ltd Managing Director Kamal Sharma said.

The higher concentration formulation allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using the novel dose, parents would need to administer only half the volume of the existing 100mg/5ml suspension, he added.

This is the company's nineteenth ANDA approval till date.

UNI